nrc

NRC-2694 is an antagonist of the epidermal growth factor receptor (EGFR). It has anti-cancer and anti-proliferative properties.

NRC-2694 dihydrochloride is an epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of solid tumors.

NRC-2694 hydrochloride is an epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of solid tumors.

AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.

Bexin-1 is an inhibitor of Munc13-4 membrane binding which targets the Munc13-4 C2 domain-membrane interface, and inhibits ionomycin-stimulated ANF-EGFP secretion.

ID110460002 is a novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist.

NRC-16 is a biologically active peptide with characteristics similar to pleurocidin, a cationic antimicrobial peptide (cationic AMP).

Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.

Somatostatin RC 102 is a peptide hormone. It regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones.

SARS-CoV-2-IN-79 (Compound 5) is an inhibitor of SARS-CoV-2 with IC50 and CC50 values of 55 μg/mL and 311.6 μg/mL, respectively. It exhibits the highest antiviral activity against (hCoV-19/Egypt/NRC-03/2020). SARS-CoV-2-IN-79 is applicable for COVID-19 research.